Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern

The neutralizing antibody responses were significantly elevated after 3rd dose of BBV152/Covaxin against the B.1 (19.11 fold) variant including Delta (16.51 fold), Beta (14.70 fold) and Omicron (18.53 fold) Variants of concern in comparison with two dose vaccine, providing assurance of a protective immune response of booster in recipients.

Automated summary

The neutralizing antibody responses significantly increased after the third dose of BBV152/Covaxin against B.1 (19.11-fold), Delta (16.51-fold), Beta (14.70-fold), and Omicron (18.53-fold) Variants of concern, compared to the two-dose vaccine, providing assurance of a protective immune response in recipients.